| Literature DB >> 29281705 |
Jung-Eun Kim1, Kyung-Mok Park2, Soon-Young Lee3, Ji-Hye Seo3, In-Soo Yoon1, Chun-Sik Bae4, Jin-Cheol Yoo5, Mi-Ae Bang6, Seung-Sik Cho1, Dae-Hun Park3.
Abstract
Inflammation is a commonly observed immune reaction, and rheumatoid arthritis is a particularly severe inflammatory disease. In this study, we used an air pouch mouse model to evaluate the anti-inflammatory potential of Allium hookeri, which has both been used as a culinary material and a traditional medicine in south-eastern Asia for many years. Allium hookeri suppressed typical symptoms of inflammation, such as condensation of the air pouch membrane, and inhibited the expression of several inducible proinflammatory cytokines such as IL-1β, IL-6, IL-13, and TNF-α. In order to determine the molecules modulating the inflammatory effect of carrageenan treatment, the components in Allium hookeri were analyzed by GC-MS, and linoleic acid, which have anti-inflammatory effect, was detected. From the results, we concluded that the anti-inflammatory effect of Allium hookeri might be attributed to linoleic acid, which could be promising candidates for anti-inflammatory drugs that have no adverse effects.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29281705 PMCID: PMC5744995 DOI: 10.1371/journal.pone.0190305
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Allium hookeri suppresses the inflammatory cells proliferation in carrageenan-induced air pouch model.
Animals were orally administered with different doses of A. hookeri 24 h and 1 h prior to carrageenan (1%) injection into the air pouch. The results are presented as mean ± S.D. (n = 9) of total leukocytes (× 103 cells/mL). * vs. control, p < 0.05; ** vs. control, p < 0.001; $ vs. 5 mg/kg indomethacin treated group, p < 0.05; # vs. carrageenan treated group, p < 0.05; & vs. 30 mg/kg A. hookeri treated group, p < 0.05.
Fig 2Allium hookeri suppresses the histopathological changes which are induced by carrageenan treatment.
a, control; b, 1% carrageenan treated group; c, 5 mg/kg indomethacin treated group; d, 30 mg/kg A. hookeri treated group; e, 300 mg/kg A. hookeri treated group, AM, air pouch membrane; Scare bar, 200 μm.
Fig 3Allium hookeri suppresses the expression of several inflammation induction markers in the skin which are upregulated by carrageenan treatment.
A is the photo of IL-1β expression, B is the photo of IL-6 expression, C is the photo of IL-13 expression, and D is the photo of TNF-α expression in the skin. a, control group; b, 1% carrageenan treated group; c, 5 mg/kg indomethacin treated group; d, 30 mg/kg A. hookeri treated group; e, 300 mg/kg A. hookeri treated group. Scare bar, 200 μm.
Analyzed compounds from Allium hookeri by GC/MS.
| NO | RT (min) | Compound name | Quality | MolecularWeight (amu) | Content (%) |
|---|---|---|---|---|---|
| 1 | 14.826 | Benzene, 1-butenyl-, (E)- | 96 | 132.094 | 0.01 |
| 2 | 15.466 | Benzene, pentyl- | 95 | 148.125 | 0.11 |
| 3 | 17.093 | Benzoic acid trimethylsilyl ester | 95 | 194.076 | 0.02 |
| 4 | 17.310 | Benzene, hexyl- | 94 | 162.141 | 0.04 |
| 5 | 18.406 | Cyclohexasiloxane, dodecamethyl- | 90 | 444.113 | 0.14 |
| 6 | 18.937 | Nonanoic acid, trimethylsilyl ester | 98 | 230.170 | 0.03 |
| 7 | 20.130 | 2,2'-Bipyridine | 96 | 156.069 | 0.29 |
| 8 | 20.488 | 2,5-Cyclohexadiene-1,4-dione, 2,6-bis(1,1-dimethylethyl)- | 96 | 220.146 | 0.04 |
| 9 | 21.714 | Silane, (dodecyloxy)trimethyl- | 97 | 258.238 | 0.22 |
| 10 | 22.245 | 2-Piperidinone, N-[4-bromo-n-butyl]- | 91 | 233.042 | 0.17 |
| 11 | 22.755 | Cyclopentadecane | 95 | 210.235 | 0.14 |
| 12 | 22.820 | Hexadecane, 2-methyl- | 97 | 240.282 | 0.15 |
| 13 | 23.102 | 2,6-Diisopropylnaphthalene | 95 | 212.157 | 2.03 |
| 14 | 23.243 | Heptadecane | 98 | 240.282 | 0.33 |
| 15 | 23.384 | 4-(3-Hydroxy-2,6,6-trimethylcyclohex-1-enyl)pent-3-en-2-one | 90 | 222.162 | 0.98 |
| 16 | 23.634 | 1H-Indene, 2,3-dihydro-1,1,3-trimethyl-3-phenyl- | 97 | 236.157 | 2.36 |
| 17 | 23.959 | 1,1'-Biphenyl, 2,2',5,5'-tetramethyl- | 96 | 210.141 | 0.43 |
| 18 | 24.014 | Hexadecane, 1-iodo- | 94 | 352.163 | 0.16 |
| 19 | 24.328 | 1,4-Benzenedicarboxylic acid, bis(trimethylsilyl) ester | 96 | 310.106 | 0.49 |
| 20 | 24.513 | 1-Eicosene | 93 | 280.313 | 2.65 |
| 21 | 24.838 | 2-Phenanthrylamine, 9,10-dihydro-3,7-dinitro- | 90 | 285.075 | 0.21 |
| 22 | 24.914 | 1-Hexacosene | 94 | 364.407 | 1.04 |
| 23 | 25.055 | Octadecane, 3-methyl- | 91 | 268.313 | 0.14 |
| 24 | 25.294 | Ethyl 13-methyl-tetradecanoate | 93 | 270.256 | 0.43 |
| 25 | 25.511 | 9-Hexadecenoic acid, methyl ester, (Z)- | 95 | 268.240 | 0.26 |
| 26 | 25.619 | Hexadecanoic acid, methyl ester | 97 | 270.256 | 0.39 |
| 27 | 26.237 | Ethyl 9-hexadecenoate | 99 | 282.256 | 1.95 |
| 28 | 26.400 | Hexadecanoic acid, ethyl ester | 99 | 284.272 | 3.27 |
| 29 | 26.552 | 1,2-Benzisothiazole, 3-(hexahydro-1H-azepin-1-yl)-, 1,1-dioxide | 91 | 264.093 | 0.13 |
| 30 | 26.671 | Cyclotetradecane, 1,7,11-trimethyl-4-(1-methylethyl)- | 93 | 280.313 | 0.11 |
| 31 | 26.715 | cis-9-Hexadecenoic acid, trimethylsilyl ester | 95 | 326.264 | 0.21 |
| 32 | 26.801 | Hexadecanoic acid, trimethylsilyl ester | 99 | 328.280 | 0.58 |
| 33 | 26.932 | Pentacosane | 94 | 352.407 | 0.27 |
| 34 | 27.268 | 9,12-Octadecadienoic acid (Z,Z)-, methyl ester | 99 | 294.256 | 1.80 |
| 35 | 27.669 | Linoleic acid ethyl ester | 99 | 308.272 | 8.02 |
| 36 | 28.179 | Octadecanoic acid, ethyl ester | 98 | 312.303 | 0.76 |
| 37 | 28.222 | Docosane | 98 | 310.360 | 3.21 |
| 38 | 28.515 | Eicosane | 94 | 282.329 | 0.34 |
| 39 | 28.580 | Octadecanoic acid, trimethylsilyl ester | 99 | 356.311 | 0.44 |
| 40 | 28.765 | Tributyl acetylcitrate | 90 | 402.225 | 0.54 |
| 41 | 29.047 | Tetratriacontane | 91 | 478.548 | 0.93 |
| 42 | 29.123 | Heneicosane | 93 | 296.344 | 0.36 |
| 43 | 29.350 | 2-Dodecen-1-yl(-)succinic anhydride | 92 | 266.188 | 0.31 |
| 44 | 30.457 | Dodecanoic acid, undecyl ester | 93 | 354.350 | 0.78 |
| 45 | 30.533 | Tricosane | 91 | 324.376 | 3.73 |
| 46 | 30.739 | Tetracosane | 95 | 338.391 | 0.85 |
| 47 | 30.869 | 24-Norcholane, 23-[2-methyl-1-(1-methylethyl)cyclopropyl]-, (5.alpha.)- | 92 | 412.407 | 2.44 |
| 48 | 30.945 | Hexacosane | 94 | 366.423 | 7.50 |
| 49 | 31.173 | Bis(2-ethylhexyl) phthalate | 91 | 390.277 | 0.85 |
| 50 | 33.028 | l-Methionine, N-neopentyloxycarbonyl-, tetradecyl ester | 90 | 459.338 | 0.40 |
| 51 | 34.818 | Nonacosane | 95 | 408.470 | 0.99 |
| 52 | 35.631 | 2-Ethoxycarbonyl-3-methyl-4-azafluorenone, 2-fluorenylimime | 90 | 430.168 | 0.29 |
| 53 | 35.750 | .alpha.-Tocopherol (vitamin E), trimethysilyl derivative | 96 | 502.421 | 1.09 |
| 54 | 36.152 | Cholestan-3-one, (5.alpha.)- | 96 | 386.355 | 0.42 |
| 55 | 36.249 | Z-14-Nonacosane | 94 | 406.454 | 0.40 |
| 56 | 38.191 | .beta.-Sitosterol trimethylsilyl ether | 97 | 486.426 | 0.49 |
| 57 | 38.527 | .alpha.-Tocopherol (vitamin E), trimethysilyl derivative | 98 | 502.421 | 1.24 |
| 58 | 39.818 | Stigmast-4-en-3-one | 96 | 412.371 | 0.79 |
Operation parameters for the GC/MS.
[1] HP Agilent GC:7890A MS:5975C.
| Condition | GC / MS [1] | |||
| Column | J&W Scientific, DB-5 cross linked 5% phenylmethyl silicone | |||
| Carrier | Helium | |||
| Split / Splitless | Splitless | |||
| Injection Volume | 1.0 μL | |||
| Detector | MS | |||
| MS Source | 230°C | |||
| MS Quad | 150°C | |||
| Analytical Temperature | Rate (°C/min) | Value (°C) | Hold time (min) | |
| initial | - | 65 | 10 | |
| Step 1 | 10 | 300 | 22 | |
| Total | 55.5 min | |||
| Electron Ionization | 70 ev | |||
| Mass Range | 50–550 amu | |||
| Scan method | Full Scan | |||